Cagrilintide vs semaglutide: what the 2026 research shows
Two weight-loss peptides, two different hunger signals. Here's how amylin and GLP-1 compare, what the trials found, and what you can actually get today.
Cagrilintide and semaglutide are two different weight-loss peptides that act on two different hunger signals. Semaglutide is a GLP-1 receptor agonist and is widely available, including as a compounded, pharmacy-grade option. Cagrilintide is an amylin analog and is still investigational, studied mostly inside the combination drug CagriSema. In head-to-head trials, semaglutide alone drove more weight loss than cagrilintide alone, and the two together drove the most. Here's how they compare, and what you can get right now.
Cagrilintide vs semaglutide at a glance
Semaglutide is an available, well-studied GLP-1 medicine; cagrilintide is an investigational amylin analog that is not yet approved on its own. They target different parts of the same fullness system, which is why researchers combined them into CagriSema.
| Cagrilintide | Semaglutide | |
|---|---|---|
| Drug class | Amylin analog | GLP-1 receptor agonist |
| Main signal | Fullness / satiety | Appetite plus slower digestion |
| Approved on its own? | No, still investigational | Yes, as branded Wegovy and Ozempic |
| Compounded option at pru? | No | Yes, pharmacy-grade compounded semaglutide |
| Solo weight loss at 68 weeks | ~11.8% | ~16.1% |
| Studied mainly as | The CagriSema combination | Standalone and in combination |
Bottom lineIf you want a weight-loss peptide you can start with a prescription today, semaglutide is the one that exists as a legitimate compounded product. Cagrilintide is promising science, not a product you can safely buy yet.
What cagrilintide and semaglutide each are
Both are peptides that lower how much you want to eat, but they copy different natural hormones. Semaglutide copies GLP-1. Cagrilintide copies amylin. Your body makes both after a meal.
Semaglutide is a GLP-1 receptor agonist. It's the active ingredient in Wegovy and Ozempic, and it's the compounded semaglutide that pru offers through a prescription. It curbs appetite, slows how fast your stomach empties, and helps steady blood sugar.
Cagrilintide is a long-acting amylin analog. Amylin is the hormone your pancreas releases alongside insulin to send the "I'm full, put the fork down" signal. Cagrilintide stretches that signal out over a week. It's studied mostly as half of CagriSema, the once-weekly combination with semaglutide.
Amylin vs GLP-1: two different fullness pathways
The short version: GLP-1 and amylin both tell your brain you've had enough, but through separate routes. Hitting both at once tends to add up to more appetite control than hitting either one alone.
- GLP-1 (semaglutide): slows stomach emptying, lowers appetite, and helps regulate blood sugar and insulin.
- Amylin (cagrilintide): reinforces the sense of fullness after eating and works alongside insulin.
- Together (CagriSema): two satiety signals stacked, which is why the combination outperformed either peptide by itself in trials.
This is the same logic behind other next-generation weight-loss peptides that hit more than one target, like the triple agonist covered in retatrutide vs tirzepatide. More targets can mean more effect, but also more that has to be proven safe over time.
Weight-loss results: what the trials found
In the phase 3 REDEFINE 1 trial, semaglutide alone drove more weight loss than cagrilintide alone, and the CagriSema combination drove the most. These are research numbers from a controlled study, not a promise about any one person.
REDEFINE 1 followed 3,417 adults with overweight or obesity (without type 2 diabetes) for 68 weeks, published in the New England Journal of Medicine in 2025.
| Treatment arm | Average weight loss at 68 weeks |
|---|---|
| CagriSema (cagrilintide + semaglutide) | ~22.7% |
| Semaglutide 2.4 mg alone | ~16.1% |
| Cagrilintide 2.4 mg alone | ~11.8% |
| Placebo | ~2.3% |
Among people who stayed on CagriSema, about 60% lost at least 20% of their body weight and about 23% lost 30% or more. Notably, the combination fell short of the 25% average target Novo Nordisk had set, a reminder that even strong science rarely lands exactly where the headlines predict.
CagriSema vs semaglutide: does adding amylin help?
Yes, in the trial the combination beat semaglutide on its own. CagriSema averaged about 22.7% weight loss versus about 16.1% for semaglutide 2.4 mg over 68 weeks. Adding the amylin signal added roughly a third more weight loss on average.
That's the appeal of CagriSema: it stacks two fullness pathways in one weekly shot. The tradeoff is that CagriSema is a single fixed-dose combination product still under FDA review, not something you can mix at home or buy piecemeal.
Worth knowingCagrilintide's biggest wins in the data come when it's paired with semaglutide, not used alone. On its own it produced the least weight loss of the active arms in REDEFINE 1.
For a same-class comparison you can act on today, semaglutide and tirzepatide are the two available options; see semaglutide vs tirzepatide.
What you can actually get in 2026
Semaglutide is available now; cagrilintide is not available as a legitimate standalone product. That's the single most practical difference between them.
Cagrilintide is investigational. As of 2026 it is still in clinical development on its own. Novo Nordisk filed for approval of the CagriSema combination in late 2025, and the FDA is reviewing it, but cagrilintide by itself has not been submitted. It's also not on the list of substances that 503A compounding pharmacies are allowed to prepare, so there is no legitimate compounded cagrilintide.
Skip the grey marketVials of cagrilintide sold online as "research-grade" or "not for human use" skip pharmacy oversight, dosing checks, and quality testing. There's no way to verify what's in them. Wait for a legitimate, prescribed product instead of ordering an investigational peptide from an unregulated seller.
Semaglutide, by contrast, has an available compounded route. pru offers compounded semaglutide prepared by a licensed 503A pharmacy when a physician confirms it's a fit. It uses the same active ingredient as the branded GLP-1 medicines, though it is not the same as Wegovy or Ozempic. More on sourcing safely in where to buy compounded semaglutide.
Side effects: how they compare
Both peptides share the same main side effects, and they're mostly digestive. In the trials, adding cagrilintide to semaglutide didn't create a brand-new category of problems, though more can happen when two appetite drugs are stacked.
- Most common: nausea, constipation, diarrhea, and vomiting, usually mild to moderate.
- These tend to be strongest early and ease as the body adjusts, which is why doses are stepped up slowly.
- As with any GLP-1, less common but more serious effects exist, which is why a prescriber reviews your history first.
Slow titration is the main tool for keeping side effects manageable. For practical steps on the semaglutide you can actually start, see semaglutide side effects and managing GLP-1 nausea.
Which one might make sense for you
For most people weighing these in 2026, the realistic choice isn't cagrilintide vs semaglutide; it's semaglutide vs tirzepatide, because those are the two you can be prescribed. Cagrilintide is worth watching, not chasing.
- Want a peptide you can start with a prescription now: semaglutide (or tirzepatide) is the answer.
- Curious about amylin as a future option: keep an eye on CagriSema's FDA review, but don't buy grey-market cagrilintide in the meantime.
- Focused on quieting food noise and appetite: that's the everyday effect people describe with GLP-1s like semaglutide, covered in GLP-1 and food noise.
Whichever direction you lean, the peptide is only half of it. Food, protein, sleep, and movement decide how much of the change sticks; see best peptides for weight loss for the fuller picture.
How pru handles cagrilintide and semaglutide
pru offers compounded semaglutide and tirzepatide today, and does not currently offer cagrilintide until there is a safe pathway for physician oversight and FDA-regulated 503A pharmacies. If cagrilintide interests you, the right move is a compliant GLP-1 you can actually start now, not an investigational peptide from an unregulated seller. Getting ahead of your metabolic health is a smart, responsible move, and pru is built to make the informed choice the accessible one.
How it works: you choose the peptide that fits your goal, and a licensed physician confirms whether it's clinically appropriate before anything ships. A physician confirms fit; the doctor doesn't pick the drug for you. Prescriptions are filled by an FDA-regulated 503A pharmacy.
- Live weight-loss options: compounded semaglutide and compounded tirzepatide, both pharmacy-grade.
- Not offered by pru: cagrilintide, CagriSema, and retatrutide, until there is a safe pathway for physician oversight and FDA-regulated 503A pharmacies.
- Pricing is a ~$50/month membership with peptides billed at cost and itemized; a higher dose costs a bit more but never carries a member markup. See pricing.
PlainlyCompounded semaglutide uses the same active ingredient as the branded GLP-1 medicines. It is not the same as Wegovy or Ozempic, and it is not FDA-approved as a compounded product.
Browse the full weight loss and metabolism lineup to see what's available, and take the next step when you're ready. Licensed physicians, pharmacy-grade medicine, and at-cost pricing are what make the proactive choice an easy one.
Related reading
Keep going with these guides on the peptides you can actually get and the ones still in trials.
- Cagrilintide guide
- Semaglutide vs tirzepatide
- Retatrutide vs tirzepatide
- Where to buy compounded semaglutide
- GLP-1 weight-loss timeline
- Compounded semaglutide at pru
Common questions
Sources & further reading
- https://www.nejm.org/doi/full/10.1056/NEJMoa2502082
- https://diabetes.org/newsroom/press-releases/cagrisema-demonstrates-significant-weight-loss-adults-obesity
- https://www.prnewswire.com/news-releases/cagrisema-2-4-mg--2-4-mg-demonstrated-22-7-mean-weight-reduction-in-adults-with-overweight-or-obesity-in-redefine-1--published-in-nejm-302487770.html
- https://www.kff.org/health-costs/poll-1-in-8-adults-say-theyve-taken-a-glp-1-drug-including-4-in-10-of-those-with-diabetes-and-1-in-4-of-those-with-heart-disease/
- https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- https://pubmed.ncbi.nlm.nih.gov/33567185/
- joinpru.com/shop/product/semaglutide